Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Patients with diabetes and recent worsening heart failure that had led to hospitalization were randomly assigned to receive sotagliflozin or placebo. At a median of 9 months, the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure was significan...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 384; no. 2; pp. 117 - 128
Main Authors: Bhatt, Deepak L, Szarek, Michael, Steg, P. Gabriel, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Voors, Adriaan A, Metra, Marco, Lund, Lars H, Komajda, Michel, Testani, Jeffrey M, Wilcox, Christopher S, Ponikowski, Piotr, Lopes, Renato D, Verma, Subodh, Lapuerta, Pablo, Pitt, Bertram
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 14.01.2021
Subjects:
Acute Kidney Injury - chemically induced
Aged
Cardiac arrhythmia
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - mortality
Congestive heart failure
Corporate sponsorship
Death
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diarrhea
Diuretics
Double-Blind Method
Ejection fraction
Female
Glucose
Glycosides - adverse effects
Glycosides - therapeutic use
Heart failure
Heart Failure - complications
Heart Failure - drug therapy
Hospitalization
Hospitalization - statistics & numerical data
Humans
Hypoglycemia
Hypotension
Hypotension - chemically induced
Male
Middle Aged
Peptides
Placebos
Sodium-glucose cotransporter
Sodium-Glucose Transporter 1 - antagonists & inhibitors
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Statistical analysis
North America
Europe
Latin America
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with diabetes and recent worsening heart failure that had led to hospitalization were randomly assigned to receive sotagliflozin or placebo. At a median of 9 months, the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure was significantly lower with sotagliflozin than with placebo.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2030183